Like pls_老虎社区_美港股上老虎

Cindyoxy
2021-10-19

Like pls

After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more

After-Hours Stock Movers: Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced

After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":850549704,"tweetId":"850549704","gmtCreate":1634610961478,"gmtModify":1634610961603,"author":{"id":3582080374471215,"idStr":"3582080374471215","authorId":3582080374471215,"authorIdStr":"3582080374471215","name":"Cindyoxy","avatar":"https://static.tigerbbs.com/6ce8843c8a2fd64a899130762430331d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/850549704","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","kind":"news","pubTimestamp":1634599410,"share":"https://ttm.financial/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TASK":"TaskUs Inc.","ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","DRMA":"Dermata Therapeutics Inc","EVER":"Everquote Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1,"symbols_score_info":{"DRMA":0.9,"ETTX":0.9,"EVER":0.9,"STLD":0.9,"TASK":0.9}},"isVote":1,"tweetType":1,"viewCount":1586,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more

评论（3）

热议股票